Investigators choice of SoC
CAAA817A12201
Phase 3 small_molecule active
Quick answer
Investigators choice of SoC for Prostate Cancer is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Prostate Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active